Roche/Genentech, Amgen, Pfizer, any company that does biotech drugs would be interested, not so much for making larger profits, but for protecting their own profit margins. If this technology spreads to other countries, they would suffer large profit losses.
Brazil is making an investment into the technology because they would rather be able to make the drug at 10% of current retail cost. Shire got approved for their Gaucher drug and they're reducing the price only by 15%. They can't/won't sell it cheaper because it's still expensive to manufacture with Chinese Hamster Ovaries. Brazil knows they can't get cheaper generics when it comes to biotech drugs... unless they own the technology themselves.
Cipla, the Indian generic drug company, who's objective is to bring down drug prices, recently announced that they would make Enbrel for 30% less. They totally destroyed the competition for AIDS drugs by charging $100 per year for AIDS drugs that used to cost $12,000 per year. Imagine if they could manufacture Enbrelfor 90% less.
Japan, Canada, United Kingdom, France, Germany, Sweden, Norway, Iceland, Denmark, Finland, Netherlands, Switzerland, New Zealand, Italy, Portugal, Greece, Spain, South Korea, Taiwan, Austria,
Belgium all have socialized medicine/universal healthcare. United States might soon. If Protalix management were smart, they'd ask for an audience in front of each of these countries Health Ministries, or have the Brazilians take this to the World Health Organization itself for discussion.